Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2005
10/20/2005WO2005097204A1 Preventives/remedies for cancer
10/20/2005WO2005097189A1 Carcinoma cell-specific apoptosis inducing agent targeting gene relevant to chromosome stabilization
10/20/2005WO2005097152A1 Turmeric extract-containing composition having improved caking capacity
10/20/2005WO2005097142A1 Biologically active compounds with anti-angiogenic properties
10/20/2005WO2005097121A1 Angiogenesis-affecting compounds and methods of use thereof
10/20/2005WO2005096693A2 Cancer prognosis and/or diagnosis method
10/20/2005WO2004076410A8 Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
10/20/2005WO2004064785A3 Cancer therapy sensitizer
10/20/2005WO2002097033A3 Antibodies that immunospecifically bind to trail receptors
10/20/2005US20050235367 Regulatory sequences capable of conferring expression of a heterologous DNA sequence in endothelial cells and uses thereof
10/20/2005US20050234248 Method of producing preparations rich in tocotrienol
10/20/2005US20050234247 New effector conjugates, process for their production and their pharmaceutical use
10/20/2005US20050234245 Estrogen receptor modulators
10/20/2005US20050234225 Comprising complementarity determining regions; recombinant host cells; fab fragments, fv fragments, diabodies, triabodies, and single domain antibodies; angiogenesis inhibitors; antitumor, antiproliferative, and anticarcinogenic agents; gene expression
10/20/2005US20050234222 Polypeptide comprising at least one alpha-helix having synthetically attached thereto a plurality of therapeutic or diagnostic moieties
10/20/2005US20050234118 Novel aryllimidazole derivatives, preparation and therapeutic used thereof
10/20/2005US20050234117 and geranylgeranyltransferase inhibitor; 3-chloromethyl-4-cyanobenzyl-5 methyl triazole; antitumor agents; prevent membrane attachment of protein p21ras and block aberrant growth of ras-transformed tumors; capable to inhibit prenylation of Ras proteins, both at enzymatic and cellular level
10/20/2005US20050234105 Method of treating of demyelinating diseases or conditions
10/20/2005US20050234094 Inhibition of protein kinases with piridinylimidazoles
10/20/2005US20050234088 Urea substituted imidazoquinoline ethers
10/20/2005US20050234083 Diamino-pyrimidines and their use as angiogenesis inhibitors
10/20/2005US20050234082 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
10/20/2005US20050234080 Mitotic kinesin inhibitors
10/20/2005US20050234077 Pyrimidine compounds and their use as modulators of chemokine receptor activity
10/20/2005US20050234059 4-(5-Methyl-2-phenyl-pyrimidin-4-yl)-1H-pyrrole-2 carboxylic acid (2-hydroxy-1-(S)-phenyl-ethyl)-amide; Mitogen-activated protein kinase inhibitor; anticarcinogenic, antiinflammatory agent,neurodegenerative disorders, restenosis, antidiabetic, antiallergen, and cardiovascular disease
10/20/2005US20050234056 Imidazoquinoline derivatives as adenosine A3 receptor ligands
10/20/2005US20050234041 Substituted 1-benzazepines and derivatives thereof
10/20/2005US20050234036 3-(2-tetrahydrofuryl-methyl)-2-thioxanthine; neuroinflammatory disorders; pain, cancers, rheumatic arthritis, neurodegenerative diseases
10/20/2005US20050234028 solid dosage form for contraceptives and hormone replacement therapy; very low moisture content to prevent ester hydrolysis; enhanced bioavailability of 17-beta-estradiol
10/20/2005US20050234022 Use of 2-alkoxyphenyl-substituted imidazotriazinones
10/20/2005US20050234017 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
10/20/2005US20050234007 RNA interference mediating small RNA molecules
10/20/2005US20050234006 RNA interference mediating small RNA molecules
10/20/2005US20050233999 That contain unmethylated cytosine-guanine (CpG) dinucleotides; stimulate an immune response and to redirect a Th2 response to a Th1 response; use with vaccines
10/20/2005US20050233995 Immunostimulatory nucleic acid molecules
10/20/2005US20050233991 Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
10/20/2005US20050233990 Anti-cancer agents comprising disintegrin genes and the treating methods
10/20/2005US20050233987 B-cell chronic lymphocytic leukemia, splenic marginal zone lymphoma (SMZL), mantle cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, and Waldenstrom syndrome
10/20/2005US20050233948 Drug complex for treatment of metastatic prostate cancer
10/20/2005US20050233943 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
10/20/2005US20050233453 6-O-sulfated N-acetylheparosan and hematopoietic stem cell growth auxiliary agent
10/20/2005US20050233452 Cell populations which co-express CD49c and CD90
10/20/2005US20050233402 Heparinase III HLGAG fragments and uses thereof
10/20/2005US20050233385 Using antibodies on cell surfaces
10/20/2005US20050233328 Methods of identifying compounds that modulate protein activity
10/20/2005US20050232952 Self emulsifying drug delivery systems for poorly soluble drugs
10/20/2005US20050232951 Low dose haptenized tumor cell and tumor cell extract immunotherapy
10/20/2005US20050232932 Compositions and methods for dendritic cell-based immunotherapy
10/20/2005US20050232915 Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer
10/20/2005US20050232912 Enzyme phosphorylating ser46 of p53
10/20/2005US20050232907 Use of herpes vectors for tumor therapy
10/20/2005US20050232906 Adjuvant preparation for the induction of specific immunity
10/20/2005US20050232862 Combination therapy for the treatment of estrogen-sensitive drugs
10/20/2005CA2563502A1 Novel water-soluble prodrug
10/20/2005CA2563123A1 Selective antagonists of a2a adenosine receptors
10/20/2005CA2562965A1 Nucleoside derivatives and therapeutic use thereof
10/20/2005CA2562954A1 Biologically active compounds with anti-angiogenic properties
10/20/2005CA2562399A1 Diphenyl - indol-2-on compounds and their use in the treatment of cancer
10/20/2005CA2561952A1 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
10/20/2005CA2561947A1 Preventives/remedies for cancer
10/20/2005CA2561621A1 Quinolone carboxylic acid derivatives for treatment of hyperproliferative conditions
10/20/2005CA2561585A1 Imidazol derivatives
10/20/2005CA2561249A1 2-aminomethylthiazole-5-carboxamides as protein kinase modulators
10/20/2005CA2561221A1 Rna interference modulators of hedgehog signaling and uses thereof
10/20/2005CA2560683A1 Novel benzothiazoles and the use thereof as medicaments
10/20/2005CA2560416A1 Angiogenesis-affecting compounds and methods of use thereof
10/19/2005EP1586900A2 Methods for identifying combinations of entities as therapeutics
10/19/2005EP1586644A2 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour development and for wound healing
10/19/2005EP1586642A2 Tumor supressor genes, proteins encoded thereby and use of said genes and proteins
10/19/2005EP1586634A1 Method of producing infectious reovirus
10/19/2005EP1586572A1 Fused pyrazolyls as anti-cancer drugs
10/19/2005EP1586571A1 Dipeptidyl peptidase inhibitors
10/19/2005EP1586567A1 Compounds useful in the treatment of inflammatory diseases
10/19/2005EP1586333A2 Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
10/19/2005EP1586325A1 Drugs containing galectin 9
10/19/2005EP1586323A1 Use of fulvestrant in the treatment of resistant breast cancer
10/19/2005EP1586322A2 Compositions for inhibition of anglogenesis
10/19/2005EP1586321A1 New use of glutamate antagonists for the treatment of cancer
10/19/2005EP1586309A1 Polymeric delivery formulations of leuprolide with improved efficacy
10/19/2005EP1585987A2 Use of adiponectin to diagnose and treat malgnancy
10/19/2005EP1585955A2 Use of isogenic human cancer cells for high-throughput screening and drug discovery
10/19/2005EP1585805A2 Phenylalanine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
10/19/2005EP1585769A2 Neuropilin-1 inhibitors
10/19/2005EP1585762A1 Means for regulating the expression of human isoforms of ant
10/19/2005EP1585750A2 Narcistatin prodrugs
10/19/2005EP1585749A1 Diazepinoindole derivatives as kinase inhibitors
10/19/2005EP1585744A1 Process for making ondansetron and intermediates thereof
10/19/2005EP1585743A1 2-(1h-indazol-6-ylamino)- benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
10/19/2005EP1585740A2 Process to prepare psorospermin
10/19/2005EP1585735A1 Hydroxamid acid derivatives as histone deacetylase (hdac) inhibitors
10/19/2005EP1585723A2 Modified retinoid compounds and their uses
10/19/2005EP1585545A2 Methods of inducing and maintaining immune tolerance
10/19/2005EP1585540A1 Medicament and use thereof for tumor therapy
10/19/2005EP1585533A2 Composition of berry extracts that prevents or inhibits angiogenesis and helicobacter pylori
10/19/2005EP1585526A2 Novel use of mifepristone and derivatives thereof as hedgehog protein signalling pathway modulators and applications of same
10/19/2005EP1423373B1 Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
10/19/2005EP1414837B1 Adenosine a3 receptor agonists
10/19/2005EP1401837B1 Purine derivatives as a2b adenosine receptor antagonists
10/19/2005EP1397170B1 Safety shield system for prefilled syringes
10/19/2005EP1370554B1 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
1 ... 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 ... 2211